Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

One NASDAQ- Listed Biotechnology Stock at Resistance Level – SRPT

Jul 08, 2026 | Team Kalkine
One NASDAQ- Listed Biotechnology Stock at Resistance Level – SRPT
Image source: Shutterstock

  • SRPT:NASDAQ
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (US$)

Sarepta Therapeutics (NASDAQ: SRPT) 

Sarepta Therapeutics (NASDAQ: SRPT) is a commercial-stage biopharmaceutical company focused on developing RNA-targeted, siRNA, gene therapy, and other genetic medicines for rare diseases. It is best known for its Duchenne muscular dystrophy portfolio, with four approved products: EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, while also advancing therapies for LGMD and other neuromuscular and CNS disorders. 

According to our previous US Dailies Report published on 'SRPT' on June 18, 2026, Kalkine recommended a 'Speculative Buy' stance on the stock at USD 16.96. This recommendation was based on fundamental analysis, and the stock has now surged by 16.69%, trading near the second resistance level.

Noted below are the details of technical summary provided in our previous report:


Disclaimer-

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…